Tibet Pharmaceutical 2025 Revenue Growth, Net Profit Decline; Chairman Salary Increase of 120,000, Average Employee Compensation 160,000

Tibet Pharmaceutical (600211) recently released its 2025 annual report, showing the company achieved an operating revenue of 2.982 billion yuan, a 6.23% increase compared to the same period last year; net profit attributable to shareholders of the listed company was 938 million yuan, a decrease of 10.78% year-on-year. This performance reflects that while the company maintains revenue growth, it faces certain pressure on profit margins.

Looking at the financial data from the past three years, Tibet Pharmaceutical’s net profit showed an initial rise followed by a decline. From 2022 to 2024, net profit increased from 370 million yuan to 1.051 billion yuan, but in 2025, it fell back to 938 million yuan. This change may be related to market conditions, cost control, or product structure adjustments.

Regarding profit distribution, the company plans to distribute cash dividends based on 60% of the net profit attributable to shareholders in the 2025 consolidated financial statements, totaling 563 million yuan for the year. Considering the 284 million yuan already paid as semi-annual cash dividends in 2025, an additional 279 million yuan (including tax) is planned to be distributed. Based on the company’s total share capital of 322 million shares, minus 4 million shares in the repurchase special securities account, each share will receive a cash dividend of 0.876 yuan (including tax).

In terms of management compensation, Chairman Chen Dabin received a pre-tax total salary of 3.5293 million yuan in 2025, an increase of 120,000 yuan from 3.4093 million yuan in 2024. Public information shows that Chen Dabin has extensive management experience, having served as Deputy General Manager of Bazhong Trust Investment Company in Dachuan area and General Manager of Hainan Tongyuan Industrial Development Corporation, and currently also serves as Chairman of Tibet Huaxi Pharmaceutical Group Co., Ltd.

Regarding employee compensation, based on “cash paid to employees and for employees / total number of employees,” Tibet Pharmaceutical’s per-employee salary in 2025 was 161,300 yuan. This data provides a reference for analyzing the company’s labor costs.

In terms of business layout, Tibet Pharmaceutical mainly engages in the research, production, and sales of capsule drugs, biological preparations, granules, and film-coated tablets. Leveraging Tibet’s unique resource advantages, the company has strong competitiveness in the Tibetan medicine field, with a product line covering multiple therapeutic areas to meet different patient needs.